US20050220859A1 - Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD) - Google Patents

Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD) Download PDF

Info

Publication number
US20050220859A1
US20050220859A1 US11/127,986 US12798605A US2005220859A1 US 20050220859 A1 US20050220859 A1 US 20050220859A1 US 12798605 A US12798605 A US 12798605A US 2005220859 A1 US2005220859 A1 US 2005220859A1
Authority
US
United States
Prior art keywords
vitamin
liposomes
copd
tracheo
bronchial tract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/127,986
Other versions
US7476380B2 (en
Inventor
Marion Frankenberger
Konrad Maier
Gerhard Scheuch
Hans-Werner Ziegler-Heitbrock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/127,986 priority Critical patent/US7476380B2/en
Publication of US20050220859A1 publication Critical patent/US20050220859A1/en
Application granted granted Critical
Publication of US7476380B2 publication Critical patent/US7476380B2/en
Assigned to HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) reassignment HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: GSF-FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to a means for the prophylaxis and therapy of disorders of the tracheo-bronchial tract, particularly of COPD (chronic obstructive pulmonary disease).
  • COPD chronic obstructive pulmonary disease
  • COPD COPD
  • the disease is characterized by chronic inflammation of the small airways ( ⁇ 2 mm) which unavoidably results in tissue reconstruction and irreparable narrowing (obstruction) of this portion of the airways.
  • tissue examination of these small airways shows increased production of mucus, increase in muciferous goblet cells, smooth muscle hypertrophy as well as infiltration with pigment-charged macrophages and CD8 positive T lymphocytes. As this process continues, tissue reconstruction and an increased deposition of connective tissue fibers occur.
  • Pathophysiologically it is the inflammation which is most important. It is characterized by an infiltration of the small airways tissue with neutrophile granulocytes, macrophages, and lymphocytes. This infiltration into the tissue is facilitated by the production of proteases by leucocytes. Mediators are produced within the tissue which promote mucus formation, stimulate muscle cells and support the generation of connective tissue (collagen) fibers by fibroblasts.
  • COPD shows a decreased maximal expiratory flow (FEV 1 ) and a slow forced emptying of the lungs.
  • FEV 1 maximal expiratory flow
  • COPD is often associated with chronic bronchitis and emphysema. However, these two diseases can be clearly distinguished from COPD.
  • chronic bronchitis is defined by a chronic productive cough for at least 3 months per year in at least 2 successive years. This disease is characterized by common bacterial infections and it can but does not necessarily lead to an irreversible obstruction.
  • Emphysema is defined as an irreversible dilatation of the airways distal of the terminal bronchia caused by degradation of the alveolar septs associated with a degradation of elastic fibers. Emphysema is not accompanied by fibrosis.
  • COPD may be differentiated as an entity from chronic bronchitis and emphysema although COPD may be accompanied by these two diseases.
  • COPD affects the small airways while chronic bronchitis occurs in the large and medium airways and emphysema in the alveoles.
  • COPD chronic bronchitis
  • fibrosis an increase in fibers
  • Chronic bronchitis does not result in tissue rearrangements.
  • emphysema destruction of the alveolar septs, is observed.
  • esters of retinoic acid and/or an ester of retinol in the preparation form of an aerosol inhalant for topical application by inhalation to prevent and treat mucous membrane disorders of the tracheo-bronchial tract in humans and animals.
  • bronchitides include acute and chronic bronchitides which show no obstruction. For example, the majority of smokers suffers from chronic bronchitis without showing airway obstruction and thus COPD. Bronchiectases are irreversible, cylindric, saccular or varicoid dilatations of the bronchia, a syndrome not belonging to the chronic obstructive disease, COPD.
  • the mucous membrane disorders of the tracheo-bronchial tract mentioned in EP 0 352 412 do not belong to the diseases to be subsumed under the term COPD. They differ from COPD particularly in that they do not show the irreversible obstruction typical for COPD.
  • COPD has been treated for example by administration of ⁇ -adrenergics/anticholinergics, theophyllin, and/or glucocorticoids.
  • Disadvantages of the above-mentioned medicaments are that their activity is only symptomatic and that they have no effect on the fatal course of COPD. Spasmolytics have a life shortening effect. Theophyllin causes arrhytmias. An important side effect of glucocorticoids is osteoporosis.
  • this object has been achieved by using vitamin A and/or the derivatives and/or the esters thereof in a therapeutically effective amount in the therapy of COPD applied in the form of an aerosol inhalant.
  • vitamin A comprises retinol, retinal, and retinoic acid and the derivatives and esters of each of these compounds as well as ⁇ -carotene and its derivatives being the precursor of vitamin A.
  • retinol may be esterified with saturated and unsaturated fatty acids such as linoleic acid, stearic acid, palmitic acid, oleic acid. This includes also chemical modifications of the fatty acids and alcohols mentioned. (See also EP 0 352 412 B1; page 11, claim 4+claim 6). Martindale, The Extra Pharmacopeia, 1982, London, The Pharmacuetical Press, and all subsequent editions is mentioned as an example. This document is incorporated herein by reference in its entirety.
  • vitamin A is applied in the form of an aerosol wherein particularly sprays and inhalants are used. This achieves the dispersion of the active agent into very small particles to transport it to the site of its therapeutic effectiveness.
  • vitamin A and the derivatives and esters thereof are present in the form of an aerosol.
  • Aerosols are fine mists usually obtained by systems under pressure. They may be obtained for example by spraying or atomizing liquids but also of dry powders. Aerosols for inhalation are different from those systems usually referred to as aerosols in that the aerosol particles are present in a size lower than 10 ⁇ m, preferably in the range of 1-10 ⁇ m.
  • the essential components of aerosol systems in the form of sprays are for example a container containing a propellant while today also aerosol systems without propellant have been developed. Furthermore, the aerosol system contains the active ingredient(s) together with conventional auxiliary agents such as for example propellants and lactose.
  • the composition of these components determines the properties of the aerosol inhalant, i.e. for example the particle size distribution, delivery rate, viscosity, etc.
  • Aerosols may be obtained as two-phase aerosols (gas and liquid) or three-phase aerosols (gas, liquid, and solid or liquid).
  • Two-phase aerosols consist of a solution of the active agent in a liquefied propellant and of the atomized propellant.
  • the solvent for example comprises the propellant or a mixture of the propellant and co-solvents such as alcohol, propylene glycol, and polyethylene glycols often used to ameliorate the solubility of the active agents.
  • Three-phase systems comprise a suspension or emulsion of the active ingredient or ingredients, respectively, together with the atomized propellants.
  • a suspension includes the active agent dispersed in the propellant system using conventional auxiliary agents such as wetting agents and/or solid carriers such as talc or colloidal silica.
  • auxiliary agents such as wetting agents and/or solid carriers such as talc or colloidal silica.
  • Propellants are known and comprise several carbohydrates, if possible those without damaging impact on the ozone layer.
  • vitamin A is encapsulated in liposomes.
  • Liposomes are aqueous compartments surrounded by a completely closed lipid bilayer. Liposomes are for example generated artificially by suspending suitable lipids in aqueous solutions. The liposomes are dispersed to generate closed vesicles of an approximately equal size. Into the aqueous solutions and the lipid membranes, respectively, may then be incorporated foreign molecules, vitamin A according to the present invention. It has been shown that vitamin A packaged into liposomes can enhance the therapeutic effect and efficiently reduce side effects. Further details in this respect are explained in the following.
  • liposomes containing at least phosphatidylcholine together with at least another phospholipid selected from phosphatidylinositol, phosphatidylserine, phosphatidic acid and cardiolipin are particularly suitable for the treatment of COPD.
  • the use of these specifically composed liposomes results in selective uptake by alveolar macrophages, a higher specificity of the therapy and a reduction of the therapeutically effective dose in association with reduced side effects.
  • the amount of phosphatidylcholine is approx. 50-95% while the amount of the other phospholipids is 5-50%, each based on 100% phospholipids.
  • phosphatidylcholine is an essential component of the liposomes while the remainder, i.e. the other 5-50%, may be one or more of the above-mentioned phospholipids.
  • the liposomes of the present invention further contain antioxidants in an amount of 10-50%.
  • Preferred in this respect is vitamin E or the derivatives thereof such as (+)- ⁇ -tocopherol acetate, ( ⁇ )- ⁇ -tocopherol acetate, (+)- ⁇ -tocopherol acid succinate.
  • the amount of phospholipids is 50%-90%.
  • the amount of vitamin A encapsulated into the liposomes may be determined by those skilled in the art by conventional medical-therapeutic testing using the pure substance. It should be understood that these tests have to be carried out in animals beforehand. It is sensible to use also the liposome formulation described as an aerosol content to achieve optimal therapeutic effects.
  • vitamin A preparations have not been described as aerosol inhalants in the form of the specifically composed liposomes described herein.
  • a pharmaceutical preparation of this type may not only be used in the treatment of COPD but e.g. also for the treatment of chronic bronchitides, emphysemas and malignant as well as benign lung diseases and generally in the treatment of disorders of the tracheo-bronchial tract.
  • the liposomes used according to the invention differ from the multilamellar liposomes known from the prior art not only in their composition but also in that they are obtained in an unilamellar state.
  • the specific combination of liposome organization, active agent, and structure results in the surprising efficacy found according to the present invention in the treatment of diseases of the tracheo-bronchial tract.
  • such phospholipids are employed which enable a selective targeting of alveolar macrophages by binding to specific receptors present on alveolar macrophages, the so-called scavenger receptors.
  • the acyl residues may be derived from arachidonic acid or from linoleic acid, palmitic acid, stearic acid and other unsaturated or saturated fatty acids
  • the acyl residues may be derived from arachidonic acid or from oleic acid, palmitic acid and other unsaturated and saturated fatty acids
  • the acyl residues may be derived from arachidonic acid or from stearic acid, decanoic acid, heptadecanoic acid, lauric acid, myristic acid, octanoic acid, oleic acid, palmitic acid, and other unsaturated or saturated fatty acids
  • Cardiolipin contains a maximum of 4 acyl residues derived from unsaturated and saturated fatty acids
  • phosphatidycholine L- ⁇ -lecithine, 1,2-diacyl-sn-glycero-3-phosphocholine (partially oxidized)
  • the acyl residues may be derived from arachidonic acid or from unsaturated or saturated fatty acids. At least 1 acylic ligand is unsaturated. The unsaturated acyl residue is partially oxidized and mediates the binding of the liposomes to scavenger receptors.
  • the liposomes employed according to the present invention preferably have a size in the range of 0.1 ⁇ m to 2 ⁇ m, particularly preferred of 0.4 ⁇ m.
  • the use of unilamellar liposomes is particularly preferred.
  • Their preparation is carried out by a type of high pressure filtration, for example using an extruder commercially available from Lipex Biomembranes company, Canada.
  • Conventional liposomes such as those described for example in the article by Parthasarathy et al., Cancer Chemother. and Pharmacol. 1999, 43(4), 277-283, are prepared by reconstitution of a dry lipid film in the desired liquid. This results in so-called multilamellar liposomes, i.e.
  • liposomes having several lipid layers surrounding the aqueous core. Such liposomes are quite heterogenous in size and may be brought to uniform size by means of sonication, as shown in Parthasarathy et al., after which, however, they still remain multilamellar. However, the multilamellar liposomes described in Parthasarathy et al. tend to form aggregates or fuse to form still larger liposomes. The use of such liposomes has been found unsuitable according to the invention.
  • the finished reconstituted liposomes may be washed prior to use so that substances which have not been incorporated are removed, on the other hand the unilamellar liposomes having only one lipid layer around the aqueous core are further processed which renders them particularly stable. It is the combination of the lipid composition described herein and the use of unilamellar liposomes which leads to a particularly significant therapeutic efficiency.
  • the object namely to deliver the active agent to specific target cells, i.e. alveolar macrophages, can only be achieved by using the liposome preparation provided according to the invention. Only this specific composition of the liposomes ensures that these are recognized and actively taken up by specific target cells. In this manner it is possible to achieve an effect of vitamin A in alveolar macrophages as the relevant target cells which has neither been known nor described up to now.
  • composition according to the invention results in a very specific modification of the metabolism of a certain type of leucocytes in the lung, namely the alveolar macrophages, to strongly affect the inflammatory process, particularly of COPD.
  • lipids are described as emulsifiers enhancing the unspecific resorption of vitamins during food intake.
  • the particular composition used according to the invention is not described, and the use for a treatment of diseases of the tracheo-bronchial tract, particularly of COPD, is not suggested. Only the specific composition used herein provides the possibility to transport vitamin A to specific target cells by which it can be actively incorporated.
  • liposomes are used as carriers to transport vitamin A to skin cells.
  • the composition used exclusively shows cosmetic but no therapeutic effects. It is unthinkable to use these compositions in the tracheo-bronchial tract.
  • the liposomes mentioned in EP-A-0 229 561 also lack the property of recognizing a particular target cell in the lung to be incorporated by this cell in a highly specific manner.
  • EP-A-0 352 412 is not prejudicial as to the novelty of and does not render obvious the object of the present invention. Although it describes the treatment of the bronchial epithelium by vitamin A it does not use the specific liposomal preparation according to the invention.
  • FIG. 1 BAL cells ⁇ vitamin A liposomes ⁇ patient E.S.: MMP-9 day 3;
  • FIG. 2 BAL cells ⁇ vitamin A liposomes ⁇ patient E.S.: TIMP-1 day 3;
  • FIG. 3 BAL cells ⁇ vitamin A liposomes ⁇ ratio MMP-9/TIMP-1: patient E.S. day 3;
  • FIG. 4 TNF ELISA of BAL cells patient: F. (sclerotic process);
  • FIG. 5 TNF ELISA of BAL cells patient: E. (sclerotic process);
  • FIG. 6 TNF ELISA of BAL cells patient: M. (EAA—farmer's lung);
  • FIG. 7 TNF ELISA of BAL cells patient: A. (giant cell pneumonia);
  • TNF tumor necrosis factor
  • MMPs matrix metalloproteases
  • COPD chronic obstructive bronchitis
  • the alveolar macrophage has been suggested to be the main producer of MMP-9 in the lung and it (and not the neutrophile granulocyte as supposed up to now) has also been discussed as the main responsible for the formation of emphysemas in most recent studies in rat. Our own studies show that MMP-9 is also increased in the serum of COPD patients.
  • An important criterion to determine the degree of the disturbance of the protease/antiprotease equilibrium is the proteinase-to-inhibitor ratio: MMP-9/TIMP-1.
  • vitamin A not only significantly inhibits MMP-9 expression but surprisingly at the same time also significantly stimulates the expression of the specific inhibitor TIMP-1.
  • the imbalance between MMPs and TIMPs may be treated, i.e. the expression of the former is inhibited while the expression of the latter is stimulated.
  • the therapy described herein counteracts tissue destruction and provides a novel and promising approach for the treatment of chronic obstructive lung disorders.
  • the particular advantages of the invention are:
  • the culture supernatants were monitored for MMP-9 and TMP-1 content using commercial ELISA kits (Amersham Pharmacia).
  • the numerals refer to ng/ml culture supernatant based on 1 ⁇ 10 6 cells.
  • the culture of BAL cells and PBMCs with liposomal vitamin A is performed as follows:
  • kits for the measurement of MMP-9 and TIMP-1 in cell culture supernatants. Specifically, the kits are:
  • the ELISAs were always performed exactly according to the manufacturer's instructions.
  • the multilamellar liposomes are converted into unilamellar liposomes having a diameter of 0.4 ⁇ m.
  • the extruder is assembled according to the instructions of the manufacturer (Lipex Biomembranes, Vancouver, Canada).
  • a filter with a pore size of 0.4 ⁇ m (Costar Nuclepore # 110 407) is inserted in addition to the preliminary filter (Drain Disc, Costar # 230 300).
  • Drain Disc, Costar # 230 300 Charge the complete volume of liposomes into the top of the device using a Pasteur pipette.
  • Extrude liposomes under pressure about 5-10 bar, not more than 40 bar) and recover in an Eppendorf reaction vial.
  • a liposome preparation should be subjected to this cycle at least three times (preferably five times).
  • subject the finished unilamellar liposomes a sterile filtration through Millipore # SLGV 013 OS filter in a sterile work bench.
  • a liposome preparation prepared in this way may be used for at least four weeks.

Abstract

The invention describes a means for the treatment of diseases of the tracheo-bronchial tract, particularly of COPD.

Description

  • The invention relates to a means for the prophylaxis and therapy of disorders of the tracheo-bronchial tract, particularly of COPD (chronic obstructive pulmonary disease).
  • Typically, COPD is encountered in smokers. The disease is characterized by chronic inflammation of the small airways (<2 mm) which unavoidably results in tissue reconstruction and irreparable narrowing (obstruction) of this portion of the airways.
  • Detailed tissue examination of these small airways shows increased production of mucus, increase in muciferous goblet cells, smooth muscle hypertrophy as well as infiltration with pigment-charged macrophages and CD8 positive T lymphocytes. As this process continues, tissue reconstruction and an increased deposition of connective tissue fibers occur.
  • Pathophysiologically, it is the inflammation which is most important. It is characterized by an infiltration of the small airways tissue with neutrophile granulocytes, macrophages, and lymphocytes. This infiltration into the tissue is facilitated by the production of proteases by leucocytes. Mediators are produced within the tissue which promote mucus formation, stimulate muscle cells and support the generation of connective tissue (collagen) fibers by fibroblasts.
  • In examinations of the respiratory mechanic, COPD shows a decreased maximal expiratory flow (FEV1) and a slow forced emptying of the lungs. COPD is often associated with chronic bronchitis and emphysema. However, these two diseases can be clearly distinguished from COPD.
  • Clinically, chronic bronchitis is defined by a chronic productive cough for at least 3 months per year in at least 2 successive years. This disease is characterized by common bacterial infections and it can but does not necessarily lead to an irreversible obstruction.
  • Emphysema is defined as an irreversible dilatation of the airways distal of the terminal bronchia caused by degradation of the alveolar septs associated with a degradation of elastic fibers. Emphysema is not accompanied by fibrosis.
  • Thus, COPD may be differentiated as an entity from chronic bronchitis and emphysema although COPD may be accompanied by these two diseases.
  • Predominantly, COPD affects the small airways while chronic bronchitis occurs in the large and medium airways and emphysema in the alveoles.
  • COPD is an irreversible process resulting in tissue rearrangements accompanied by a fibrosis (an increase in fibers). Chronic bronchitis does not result in tissue rearrangements. In emphysema, destruction of the alveolar septs, is observed.
  • An increase in neutrophile granulocytes, macrophages, and CD8 cells in the small airways has been found to be typical in COPD. All inflammatory cells are involved in chronic bronchitis while leucocytes are of no major importance in emphysema.
  • It is known from EP 0 352 412 to use esters of retinoic acid and/or an ester of retinol in the preparation form of an aerosol inhalant for topical application by inhalation to prevent and treat mucous membrane disorders of the tracheo-bronchial tract in humans and animals. These so-called bronchitides include acute and chronic bronchitides which show no obstruction. For example, the majority of smokers suffers from chronic bronchitis without showing airway obstruction and thus COPD. Bronchiectases are irreversible, cylindric, saccular or varicoid dilatations of the bronchia, a syndrome not belonging to the chronic obstructive disease, COPD.
  • Therefore, the mucous membrane disorders of the tracheo-bronchial tract mentioned in EP 0 352 412 do not belong to the diseases to be subsumed under the term COPD. They differ from COPD particularly in that they do not show the irreversible obstruction typical for COPD.
  • Up to now, COPD has been treated for example by administration of β-adrenergics/anticholinergics, theophyllin, and/or glucocorticoids. Disadvantages of the above-mentioned medicaments are that their activity is only symptomatic and that they have no effect on the fatal course of COPD. Spasmolytics have a life shortening effect. Theophyllin causes arrhytmias. An important side effect of glucocorticoids is osteoporosis.
  • It is an object of the present invention to provide a novel means for the treatment of COPD which avoids the disadvantages known from the prior art.
  • According to the invention, this object has been achieved by using vitamin A and/or the derivatives and/or the esters thereof in a therapeutically effective amount in the therapy of COPD applied in the form of an aerosol inhalant.
  • The term “derivatives” of vitamin A comprises retinol, retinal, and retinoic acid and the derivatives and esters of each of these compounds as well as β-carotene and its derivatives being the precursor of vitamin A. For example, retinol may be esterified with saturated and unsaturated fatty acids such as linoleic acid, stearic acid, palmitic acid, oleic acid. This includes also chemical modifications of the fatty acids and alcohols mentioned. (See also EP 0 352 412 B1; page 11, claim 4+claim 6). Martindale, The Extra Pharmacopeia, 1982, London, The Pharmacuetical Press, and all subsequent editions is mentioned as an example. This document is incorporated herein by reference in its entirety.
  • For administration by inhalation, vitamin A is applied in the form of an aerosol wherein particularly sprays and inhalants are used. This achieves the dispersion of the active agent into very small particles to transport it to the site of its therapeutic effectiveness.
  • According to the invention, vitamin A and the derivatives and esters thereof are present in the form of an aerosol. Aerosols are fine mists usually obtained by systems under pressure. They may be obtained for example by spraying or atomizing liquids but also of dry powders. Aerosols for inhalation are different from those systems usually referred to as aerosols in that the aerosol particles are present in a size lower than 10 μm, preferably in the range of 1-10 μm.
  • The essential components of aerosol systems in the form of sprays are for example a container containing a propellant while today also aerosol systems without propellant have been developed. Furthermore, the aerosol system contains the active ingredient(s) together with conventional auxiliary agents such as for example propellants and lactose. The composition of these components determines the properties of the aerosol inhalant, i.e. for example the particle size distribution, delivery rate, viscosity, etc.
  • Aerosols may be obtained as two-phase aerosols (gas and liquid) or three-phase aerosols (gas, liquid, and solid or liquid). Two-phase aerosols consist of a solution of the active agent in a liquefied propellant and of the atomized propellant. The solvent for example comprises the propellant or a mixture of the propellant and co-solvents such as alcohol, propylene glycol, and polyethylene glycols often used to ameliorate the solubility of the active agents.
  • Three-phase systems comprise a suspension or emulsion of the active ingredient or ingredients, respectively, together with the atomized propellants. A suspension includes the active agent dispersed in the propellant system using conventional auxiliary agents such as wetting agents and/or solid carriers such as talc or colloidal silica. Propellants are known and comprise several carbohydrates, if possible those without damaging impact on the ozone layer.
  • An inhalation is only possible if the solutions for inhalation are atomized into very small particles of a size in the range of 1-10 μm. Only those finely dispersed aerosols can be inhaled at all. An inhalation is contra-indicated in the case of conventional aerosols. For further information with respect to aerosol inhalants see for example the US Pharmacopoeia which is incorporated herein by reference in its entirety.
  • In a preferred embodiment of the invention, vitamin A is encapsulated in liposomes. Liposomes are aqueous compartments surrounded by a completely closed lipid bilayer. Liposomes are for example generated artificially by suspending suitable lipids in aqueous solutions. The liposomes are dispersed to generate closed vesicles of an approximately equal size. Into the aqueous solutions and the lipid membranes, respectively, may then be incorporated foreign molecules, vitamin A according to the present invention. It has been shown that vitamin A packaged into liposomes can enhance the therapeutic effect and efficiently reduce side effects. Further details in this respect are explained in the following.
  • It has been shown that liposomes containing at least phosphatidylcholine together with at least another phospholipid selected from phosphatidylinositol, phosphatidylserine, phosphatidic acid and cardiolipin are particularly suitable for the treatment of COPD. The use of these specifically composed liposomes results in selective uptake by alveolar macrophages, a higher specificity of the therapy and a reduction of the therapeutically effective dose in association with reduced side effects.
  • The amount of phosphatidylcholine is approx. 50-95% while the amount of the other phospholipids is 5-50%, each based on 100% phospholipids. Thus, phosphatidylcholine is an essential component of the liposomes while the remainder, i.e. the other 5-50%, may be one or more of the above-mentioned phospholipids. The liposomes of the present invention further contain antioxidants in an amount of 10-50%. Preferred in this respect is vitamin E or the derivatives thereof such as (+)-α-tocopherol acetate, (±)-α-tocopherol acetate, (+)-α-tocopherol acid succinate. The amount of phospholipids is 50%-90%.
  • The amount of vitamin A encapsulated into the liposomes may be determined by those skilled in the art by conventional medical-therapeutic testing using the pure substance. It should be understood that these tests have to be carried out in animals beforehand. It is sensible to use also the liposome formulation described as an aerosol content to achieve optimal therapeutic effects.
  • To date, vitamin A preparations have not been described as aerosol inhalants in the form of the specifically composed liposomes described herein. A pharmaceutical preparation of this type may not only be used in the treatment of COPD but e.g. also for the treatment of chronic bronchitides, emphysemas and malignant as well as benign lung diseases and generally in the treatment of disorders of the tracheo-bronchial tract.
  • The liposomes used according to the invention differ from the multilamellar liposomes known from the prior art not only in their composition but also in that they are obtained in an unilamellar state. The specific combination of liposome organization, active agent, and structure results in the surprising efficacy found according to the present invention in the treatment of diseases of the tracheo-bronchial tract.
  • Preferably, such phospholipids are employed which enable a selective targeting of alveolar macrophages by binding to specific receptors present on alveolar macrophages, the so-called scavenger receptors. This includes the following phospholipids:
    • 1. phosphatidylinositol (1,2-diacyl-sn-glycero-3-phospho-[1-D-myo-inositol])
  • The acyl residues may be derived from arachidonic acid or from linoleic acid, palmitic acid, stearic acid and other unsaturated or saturated fatty acids
    • 2. phosphatidylserine (1,2-diacyl-sn-glycero-3-phospho-serine)
  • The acyl residues may be derived from arachidonic acid or from oleic acid, palmitic acid and other unsaturated and saturated fatty acids
    • 3. phosphatidic acid (1,2-diacyl-sn-glycero-3-phosphate)
  • The acyl residues may be derived from arachidonic acid or from stearic acid, decanoic acid, heptadecanoic acid, lauric acid, myristic acid, octanoic acid, oleic acid, palmitic acid, and other unsaturated or saturated fatty acids
    • 4. cardiolipin (diphosphatidylglycerol])
  • Cardiolipin contains a maximum of 4 acyl residues derived from unsaturated and saturated fatty acids
    • 5. phosphatidycholine (L-α-lecithine, 1,2-diacyl-sn-glycero-3-phosphocholine) (partially oxidized)
  • The acyl residues may be derived from arachidonic acid or from unsaturated or saturated fatty acids. At least 1 acylic ligand is unsaturated. The unsaturated acyl residue is partially oxidized and mediates the binding of the liposomes to scavenger receptors.
  • The liposomes employed according to the present invention preferably have a size in the range of 0.1 μm to 2 μm, particularly preferred of 0.4 μm. The use of unilamellar liposomes is particularly preferred. Their preparation is carried out by a type of high pressure filtration, for example using an extruder commercially available from Lipex Biomembranes company, Canada. Conventional liposomes such as those described for example in the article by Parthasarathy et al., Cancer Chemother. and Pharmacol. 1999, 43(4), 277-283, are prepared by reconstitution of a dry lipid film in the desired liquid. This results in so-called multilamellar liposomes, i.e. liposomes having several lipid layers surrounding the aqueous core. Such liposomes are quite heterogenous in size and may be brought to uniform size by means of sonication, as shown in Parthasarathy et al., after which, however, they still remain multilamellar. However, the multilamellar liposomes described in Parthasarathy et al. tend to form aggregates or fuse to form still larger liposomes. The use of such liposomes has been found unsuitable according to the invention. By using the extruder described above and has been mentioned exemplarily only the finished reconstituted liposomes may be washed prior to use so that substances which have not been incorporated are removed, on the other hand the unilamellar liposomes having only one lipid layer around the aqueous core are further processed which renders them particularly stable. It is the combination of the lipid composition described herein and the use of unilamellar liposomes which leads to a particularly significant therapeutic efficiency.
  • The object, namely to deliver the active agent to specific target cells, i.e. alveolar macrophages, can only be achieved by using the liposome preparation provided according to the invention. Only this specific composition of the liposomes ensures that these are recognized and actively taken up by specific target cells. In this manner it is possible to achieve an effect of vitamin A in alveolar macrophages as the relevant target cells which has neither been known nor described up to now.
  • The use of the pharmaceutical composition according to the invention results in a very specific modification of the metabolism of a certain type of leucocytes in the lung, namely the alveolar macrophages, to strongly affect the inflammatory process, particularly of COPD.
  • It has not been known from the prior art that cellular targeting can be achieved by using a particular liposomal composition to bring about novel therapeutic possibilities. Cellular targeting of the liposome composition selected according to the invention is the prerequisite for the solution of the problem underlying the present invention in other, i.e. not-alveolar macrophages, another effect of vitamin A may be considered which could even compromise the above-mentioned object. Such an effect has been described for example to occur in rat osteoblasts.
  • In Kirilenko V. N. and Gregoriadis G., J. Drug Targeting 1993, 1(4), 361-368 lipids are described as emulsifiers enhancing the unspecific resorption of vitamins during food intake. The particular composition used according to the invention is not described, and the use for a treatment of diseases of the tracheo-bronchial tract, particularly of COPD, is not suggested. Only the specific composition used herein provides the possibility to transport vitamin A to specific target cells by which it can be actively incorporated.
  • In EP-A-0 229 561 liposomes are used as carriers to transport vitamin A to skin cells. The composition used exclusively shows cosmetic but no therapeutic effects. It is unthinkable to use these compositions in the tracheo-bronchial tract. The liposomes mentioned in EP-A-0 229 561 also lack the property of recognizing a particular target cell in the lung to be incorporated by this cell in a highly specific manner.
  • In addition, also EP-A-0 352 412 is not prejudicial as to the novelty of and does not render obvious the object of the present invention. Although it describes the treatment of the bronchial epithelium by vitamin A it does not use the specific liposomal preparation according to the invention.
  • In the following the invention will be described with respect to the accompanying Figures. The Figures show:
  • FIG. 1: BAL cells±vitamin A liposomes−patient E.S.: MMP-9 day 3;
  • FIG. 2: BAL cells±vitamin A liposomes−patient E.S.: TIMP-1 day 3;
  • FIG. 3: BAL cells±vitamin A liposomes−ratio MMP-9/TIMP-1: patient E.S. day 3;
  • FIG. 4: TNF ELISA of BAL cells patient: F. (sclerotic process);
  • FIG. 5: TNF ELISA of BAL cells patient: E. (sclerotic process);
  • FIG. 6: TNF ELISA of BAL cells patient: M. (EAA—farmer's lung);
  • FIG. 7: TNF ELISA of BAL cells patient: A. (giant cell pneumonia);
  • BAL=bronchio-alveolar lavage
  • TNF=tumor necrosis factor
  • AM=alveolar macrophages
  • ELISA=enzyme linked immunosorbent assay
  • In the following, the present invention will be described in more detail with respect to Examples to which the invention, however, is not limited.
  • There is increasing evidence that disorders in the protease/protease inhibitor equilibrium are the cause underlying the pathogenesis of chronic lung diseases. Thus, it has been demonstrated that matrix metalloproteases (MMPs) secreted by alveolar macrophages lead to irreversible damages of the lung tissue and thus result in a decrease of respiratory functions. This is particularly true for patients suffering from chronic obstructive bronchitis (COPD). Among the MMPs in COPD, it is particularly the secretion of MMP-9 metalloprotease which is increased in the airways and alveoles and can no longer be completely neutralized by its natural antagonist TIMP-1 (tissue inhibitor of metalloprotease). The alveolar macrophage has been suggested to be the main producer of MMP-9 in the lung and it (and not the neutrophile granulocyte as supposed up to now) has also been discussed as the main responsible for the formation of emphysemas in most recent studies in rat. Our own studies show that MMP-9 is also increased in the serum of COPD patients. An important criterion to determine the degree of the disturbance of the protease/antiprotease equilibrium is the proteinase-to-inhibitor ratio: MMP-9/TIMP-1.
  • Using an in vitro system with alveolar macrophages it has been shown according to the invention that vitamin A not only significantly inhibits MMP-9 expression but surprisingly at the same time also significantly stimulates the expression of the specific inhibitor TIMP-1. These effects were most pronounced if vitamin A was previously packaged into the specifically composed liposomes described above which ensures the specific uptake by alveolar macrophages.
  • Unexpectedly, by using liposome-encapsulated vitamin A the ratio of MMP-9/TIMP-1 could be clearly reduced, i.e. by a factor of 12. This means an efficient reduction of the tissue destructive potential of the proteolytic system by vitamin A. On the basis of these studies the present therapy approach for the treatment of COPD and lung emphysema has been established. The composition of the liposomes is already described above. The following Examples explain in detail the preparation of the liposomes.
  • The effect of vitamin A on metalloproteases is known. However, the results achieved by the administration of vitamin A are very contradictory. While in several test systems there has been reported a reduction in metalloprotease concentration by inhibition of the expression of the respective coding genes, others describe an increased expression and thereby an increased concentration of metalloproteases. Park and Kim, Mol. Cells 1999, 9(2):119-26 describe that due to the effect of retinoic acid enzymes having gelatinase activities which are to be counted among the metalloproteases were increased in their activity, particularly the expression of these metalloproteases was increased. The publication of Overall, Journal of Cellular Physiology, 1995, 164(1):17-25 reports that retinoic acid increases the expression of metalloproteases in rat osteoblasts while simultaneously the mRNA levels of TMP-1 were clearly reduced depending on the dose of retinoic acid administrated. The work of Heath et al., Biochemical and Biophysical Research Communications 1990, 168(3):1171-1176 describes that the TIMP levels decreased to 0 under the influence of retinol.
  • Considering the above-described state of the art it is a surprising result for those skilled in the art that by the effect of vitamin A, i.e. retinoic acid and retinol, not only a clear inhibition of the expression of MMP-9 metalloprotease in alveolar macrophages and blood monocytes but simultaneously also a stimulation of the TIMP-1 inhibitor is achieved.
  • In the frame of experiments to determine the uptake of liposomes according to the invention by monocytes in blood there were used as test systems also various conventional cell lines of different origin and examined with respect to their capability to take up liposomes. Particularly, cells of myelomonocytic origin were used such as the cell lines HL-60, U937, THP-1, and Mono Mac 6 (mentioned in the order of increasing degree of maturity). Thus, the monocytic human cell line Mono Mac 6 has reached the highest degree of maturity on its way to develop into a macrophage. However, this cell has taken up almost no liposomes which is in contrast to the assumption that a cell with a higher degree of differentiation also shows a higher phosphatidylserine receptor expression. Insofar it was also not obvious that alveolar macrophages would take up these liposomes in a selective manner. Furthermore, it was unpredictable into which type of macrophage a blood monocyte would develop since there are significant differences not only with respect to morphology and function. Moreover, it was unknown which cells are endowed with what kind of phosphatidylserine receptor. Particularly, it was unknown that a phosphatidylserine receptor is present on alveolar macrophages. For this reason, not only the effect of vitamin A in the treatment of COPD and lung emphysema was surprising but also the increased efficacy of vitamin A due to its administration in the form of liposomes, particularly by specifically composed liposomes as presently described.
  • By treatment of COPD and lung emphysema with vitamin A the imbalance between MMPs and TIMPs may be treated, i.e. the expression of the former is inhibited while the expression of the latter is stimulated.
  • The therapy described herein counteracts tissue destruction and provides a novel and promising approach for the treatment of chronic obstructive lung disorders. Among others, the particular advantages of the invention are:
      • use of a smaller dose due to selective uptake of liposomally packaged vitamin A by the alveolar macrophages which are the most important source of metalloproteases;
      • a highly efficient effect of vitamin A is achieved by the simultaneous impact on two agonists in equilibrium of the proteolytic system of the lung;
      • the protease/antiprotease equilibrium in the lung is returned to normal;
      • liposomally packaged vitamin A is stored in the form of a depot;
      • this results in a lower amount of vitamin A released into the blood circulation, the active agent remains directly at the site of activity, i.e. the lung, and the systemic side effects are decreased.
  • The following experiments demonstrate the surprising effects of vitamin A administration, particularly in the form of liposomes. For this purpose, human alveolar macrophages (AMs) were obtained via bronchial lavage. The AMs were seeded into Mono Mac 6 medium+10% FCS onto a 24 well “low attachment” plate (Costar) using 1×106 cells in a volume of 1 ml per each sample. Additions of vitamin A liposomes or of the pure substances, respectively, were carried out. Cells for RT-PCR or culture supernatant for protein determinations by means of ELISA, respectively, were harvested from parallel samples each on day 1, day 3, and day 4. Specifically, the following samples were prepared:
      • β=control sample, AMs in medium only
      • Lipleer=empty liposomes
      • LipVitA=liposomes containing vitamin A (retinoic acid, Sigma R-2625) 5 μM final
      • VitA=pure vitamin A (retinoic acid, Sigma R-2625) 5 μM final
      • LipPalm=liposomes containing all-trans retinol palmitate (Sigma R-3375) 3 μM final
      • Palmitat=all-trans retinol palmitate (Sigma R-3375) 3 μM final
  • The culture supernatants were monitored for MMP-9 and TMP-1 content using commercial ELISA kits (Amersham Pharmacia). In each case the numerals refer to ng/ml culture supernatant based on 1×106 cells.
  • The data given show the results obtained on day 3 following vitamin A addition. On day 1, no effect could be observed on the protein level (but on the RNA level); the data obtained on day 4 were the same as those of day 3: while due to liposomal and free vitamin A the MMP-9 expression is strongly reduced a simultaneous increase in TIMP-1 is observed. In each case the effect of liposomal vitamin A is superior to that of free vitamin A. This opposite regulation of MMP-9 and TIMP-1 also explains the drastic effect on the MMP-9/TIMP-1 ratio of the vitamin A treatment.
  • The culture of BAL cells and PBMCs with liposomal vitamin A is performed as follows:
  • Material:
      • RPMI 1640 (Biochrom # F1415, Berlin), L-glutamine 2 mM (Gibco # 25030-024), penicillin 200 U/ml, streptomycin 200 μg/ml (Gibco # 15140-114), non-essential amino acids (NEAA) 1-2x (Gibco # 11140-35), OPI supplement (contains oxalacetate, Na pyruvate and insulin) 10 ml per 1 liter (Sigma # O-5003). Following filtration through a Gabro ultrafilter U 2000 (Martinsried, Germany) to remove LPS addition of 10% FCS, LPS tested.
      • Costar low attachment 24 well plates # 3473 (Bodenheim, Germany) 1×106 BAL cells (=cells obtained by brocho-alveolar lavage containing alveolar macrophages in an amount of about 80%) or 1.5×106 PBMCs (=peripheral blood mononuclear cells isolated via LymphoPrep gradient (Nycomed, Norway)), respectively, in a volume of 1 ml were used per sample. Pretreat the 24 well low attachment cell culture plate according to the manufacturer's instructions. For this purpose, fill the respective wells with 1 ml of medium and incubate for 20 min at 37° C. in an incubator. Afterwards remove the medium and replace by cell suspension. Add the liposomes loaded with vitamin A in a final concentration of 5×10−6 M. Prepare parallel samples with pure vitamin A and empty liposomes as controls. For the measurement of MMP-9 and TIMP-1 in the culture supernatant and for determination of mRNA expression incubate the cells in an incubator for three days at 37° C. Afterwards resuspend the cells carefully and first remove 2×104 cells per PCR lysate for lysis in 200 μl of RNAclean (AGS, Heidelberg, Germany)in an Eppendorf reaction vial. Store these PCR lysates at −20° C. until further use. Transfer the remaining cell suspension into an Eppendorf vial and centrifuge for 5 min at 14,000×g. Remove the supernatant, transfer into a fresh vial and store at −80° C. until measurement.
        Summary of the Samples:
      • 1. BAL cells or PBMCs, respectively without any addition
      • 2. BAL cells or PBMCs, respectively + empty liposomes
      • 3. BAL cells or PBMCs, respectively + liposomes vitA 5 μM final
      • 4. BAL cells or PBMCs, respectively pure vitA 5 μM final
        Determinations of MMP-9 and TIMP-1 on the Protein Level by ELISA
  • For the measurement of MMP-9 and TIMP-1 in cell culture supernatants commercially available ELISA kits of Amersham Pharmacia Biotech company (Freiburg, Germany) are used. Specifically, the kits are:
      • Matrix metalloproteinase-9 (MMP-9), human, ELISA system: code RPN 2614
      • Tissue inhibitor of metalloproteinases-1 (TIMP-1), human, ELISA system: code RPN 2611
      • Matrix metalloproteinase-9 (MMP-9), human, activity system: code RPN 2630
  • The ELISAs were always performed exactly according to the manufacturer's instructions.
  • Determinations of mRNA Expression of MMP-9 and TIMP-1 by Means of Semi-quantitative RT-PCR
  • The method used is established and already published in several publications. Therefore, only some points are listed for description.
      • isolation of total RNA using the RNAclean method
      • transcription of the RNA into cDNA using oligo-dT
      • amplification of the cDNA using specific primers for MMP-9, TIMP-1, and α-enolase as a control
      • confirmation by agarose gel
        Preparation of Liposomes Containing 5×10−4 M of All-trans Retinoic Acid
        Reagents:
      • phosphatidyl choline: 1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholin=POPC
      • phosphatidyl serine: 1,1-dioleyl-sn-glycero-3-phospho-L-serine, mono sodium salt=OOPS
      • all-trans retinoic acid (vitamin A): Sigma # R-2625 (Deisenhofen, Germany) 10 mM stock solution in absolute ethanol
      • (±)-α-tocopherol (vitamin E): Sigma # T-3251 (Deisenhofen) stock solution 20 mg/ml in absolute ethanol
  • Be careful to ensure that all reagents used are endotoxin-free (LPS-free) and render all glass ware LPS-free by baking at 180° C. for 3 h. Charge 17.5 mg POPC and 7.5 mg OOPS into a sterile freezing tube (NUNC) to prepare 1 ml liposomes. Dissolve lipids by addition of 1 ml chloroform (Merck). Transfer the complete solution into a 250 ml Duran glass round bottom flask and add 50 μl of the vitamin A stock solution with a pipette. Additionally add 10 μl of the vitamin E stock solution to protect lipids and vitamin A from oxidation. Under sterile conditions, evaporate the chloroform during gentle heating (not more than 42° C.) and rotation of the flask until a whitish lipid film forms at the inner glass surface. Reconstitute the liposomes by addition of 1 ml sterile LPS-free phosphate buffer (PBS) and agitation of the flask. For complete reconstitution of the liposomes let the preparation rest for about 20 min at room temperature (protected from light). Afterwards, transfer the resulting multilamellar liposomes into a sterile 1.5 ml Eppendorf reaction vial. For control purposes, always prepare ‘empty’ liposomes without vitamin A addition. To remove vitamin A not encapsulated into liposomes centrifuge the liposome preparation in an Eppendorf table top centrifuge at 14,000×g for 5 min. Pipette off the supernatant and restore the volume to 1 ml using fresh PBS. Repeat this washing step for a total of 6 times.
  • In the subsequent extrusion process the multilamellar liposomes are converted into unilamellar liposomes having a diameter of 0.4 μm. For this purpose, the extruder is assembled according to the instructions of the manufacturer (Lipex Biomembranes, Vancouver, Canada). To obtain 0.4 μm liposomes a filter with a pore size of 0.4 μm (Costar Nuclepore # 110 407) is inserted in addition to the preliminary filter (Drain Disc, Costar # 230 300). Charge the complete volume of liposomes into the top of the device using a Pasteur pipette. Extrude liposomes under pressure (about 5-10 bar, not more than 40 bar) and recover in an Eppendorf reaction vial. Recharge these liposomes into the top of the device and repeat (the membrane filter may be used up to 9 times). A liposome preparation should be subjected to this cycle at least three times (preferably five times). For use in cell culture, subject the finished unilamellar liposomes a sterile filtration through Millipore # SLGV 013 OS filter in a sterile work bench. A liposome preparation prepared in this way may be used for at least four weeks.
  • Characterization of the Liposomes
      • unilamellar
      • 0.4 μm in diameter
      • confirmation of functionality may be carried out using a specific staining method and analysis via flow cytometer (may be described in detail if necessary)

Claims (5)

1-21. (canceled)
22. A method for treating a tracheo-bronchial tract disease in a subject in need thereof, the method comprising:
(a) providing a subject with a tracheo-bronchial tract disease; and
(b) administering to the subject a pharmaceutical composition in the form of an aerosol inhalant comprising a therapeutically effective amount of vitamin A, a vitamin A derivative, a vitamin A ester, or a combination thereof within a liposome, wherein a lipid bilayer of said liposome comprises phosphatidylcholine and another phospholipid selected from the group consisting of phosphatidylinositol, phosphatidylserine, and cardiolipin.
23. The method of claim 22, wherein the tracheo-bronchial tract disease is selected from the group consisting of chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, and a malignant or benign lung disease.
24. The method of claim 23, wherein the tracheo-bronchial tract disease is chronic obstructive pulmonary disease (COPD).
25. The method of claim 24, wherein the vitamin A, vitamin A derivative, vitamin A ester, or combination thereof is selected from the group consisting of retinol, retinal, retinoic acid, derivatives and esters thereof, and β-carotene and derivatives thereof.
US11/127,986 2000-03-13 2005-05-12 Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD) Expired - Fee Related US7476380B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/127,986 US7476380B2 (en) 2000-03-13 2005-05-12 Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10012151.9 2000-03-13
DE10012151A DE10012151A1 (en) 2000-03-13 2000-03-13 Aerosol inhalant containing vitamin A compound in liposomes based on phosphatidylcholine, useful for treatment of tracheo-bronchial illnesses, especially chronic obstructive pulmonary disease
PCT/EP2001/002832 WO2001068081A1 (en) 2000-03-13 2001-03-13 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (copd)
US10/241,181 US7074389B2 (en) 2000-03-13 2002-09-11 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (COPD)
US11/127,986 US7476380B2 (en) 2000-03-13 2005-05-12 Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/241,181 Division US7074389B2 (en) 2000-03-13 2002-09-11 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (COPD)

Publications (2)

Publication Number Publication Date
US20050220859A1 true US20050220859A1 (en) 2005-10-06
US7476380B2 US7476380B2 (en) 2009-01-13

Family

ID=7634524

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/241,181 Expired - Fee Related US7074389B2 (en) 2000-03-13 2002-09-11 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (COPD)
US11/127,986 Expired - Fee Related US7476380B2 (en) 2000-03-13 2005-05-12 Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/241,181 Expired - Fee Related US7074389B2 (en) 2000-03-13 2002-09-11 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (COPD)

Country Status (8)

Country Link
US (2) US7074389B2 (en)
EP (1) EP1263422B1 (en)
JP (1) JP2003528055A (en)
AT (1) ATE319439T1 (en)
AU (1) AU2001252192A1 (en)
DE (2) DE10012151A1 (en)
ES (1) ES2260213T3 (en)
WO (1) WO2001068081A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080107723A1 (en) * 2006-09-28 2008-05-08 Perkins Walter R Methods of Treating Pulmonary Distress
US20090105179A1 (en) * 2007-09-14 2009-04-23 Nitto Denko Corporation Drug carriers
US8574623B2 (en) 2004-12-22 2013-11-05 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US8652526B2 (en) 2004-12-22 2014-02-18 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
US8686052B2 (en) 2007-03-30 2014-04-01 Nitto Denko Corporation Targeting agent for cancer cell or cancer-associated fibroblast
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US11154621B2 (en) * 2017-06-27 2021-10-26 Ohio State Innovation Foundation Liponucleotide-based therapy for COPD

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10012151A1 (en) 2000-03-13 2001-09-27 Gsf Forschungszentrum Umwelt Aerosol inhalant containing vitamin A compound in liposomes based on phosphatidylcholine, useful for treatment of tracheo-bronchial illnesses, especially chronic obstructive pulmonary disease
JP2005507934A (en) * 2001-10-30 2005-03-24 ネクター セラピューティックス エイエル，コーポレイション Water-soluble polymer conjugate of retinoic acid
US20030219465A1 (en) * 2002-05-23 2003-11-27 Suresh Kumar Gidwani Composition for delivery of dithranol
WO2006025395A1 (en) * 2004-08-31 2006-03-09 Yasuhiko Shimizu Drug and treating system for chronic obstructive pulmonary disease by using carrier-free cell growth factor
JP2009221164A (en) 2008-03-17 2009-10-01 Nitto Denko Corp Drug for treating pulmonary fibrosis
US20160038593A1 (en) * 2004-12-22 2016-02-11 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
FR2889957B1 (en) * 2005-09-01 2008-06-27 Gerard Pieroni USE OF PHOSPHOLIPID DHA FOR THE PREPARATION OF A COMPOSITION FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY.
JP5342834B2 (en) * 2008-09-05 2013-11-13 日東電工株式会社 Treatment agent for myelofibrosis
US9707185B2 (en) * 2007-05-07 2017-07-18 Board Of Supervisors Of Louisana State University And Agricultural And Mechanical College Water-soluble nanoparticles containing water-insoluble compounds
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
JP5210699B2 (en) * 2008-04-18 2013-06-12 ピアス株式会社 Retinoid stabilizing composition, skin external preparation and cosmetic containing the composition
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
TWI658830B (en) 2011-06-08 2019-05-11 日東電工股份有限公司 Retinoid-liposomes for enhancing modulation of hsp47 expression
JP5727557B2 (en) * 2013-08-21 2015-06-03 日東電工株式会社 Treatment agent for pulmonary fibrosis
JP2023528404A (en) * 2020-06-01 2023-07-04 アドベント セラピューティクス インコーポレイテッド Pharmaceutical compositions containing insoluble active ingredients

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5306483A (en) * 1989-07-27 1994-04-26 Scientific Development & Research, Inc. Phospholipid delivery system
US5556611A (en) * 1988-05-04 1996-09-17 Hermes Fabrik Pharmazeutischer Praparate Vitamin A aerosol-inhalant preparations and method
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
FR2591105B1 (en) * 1985-12-11 1989-03-24 Moet Hennessy Rech PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, OR COSMETIC, BASED ON HYDRATED LIPID LAMELLAR PHASES OR LIPOSOMES CONTAINING A RETINOIDE OR A STRUCTURAL ANALOG OF SUCH A RETINOID AS A CAROTENOID.
DE69013557D1 (en) * 1989-04-21 1994-12-01 Otsuka Pharma Co Ltd Bioactive compounds coupled to liposomes and their use in pharmaceutical preparations.
FR2658418B1 (en) * 1990-02-20 1994-09-02 Synthelabo PHARMACEUTICAL COMPOSITIONS BASED ON PHOSPHOLIPIDS.
AU3361595A (en) * 1994-08-08 1996-03-07 Argus Pharmaceuticals, Inc. Formulation and use of carotenoids in treatment of cancer
AR002009A1 (en) * 1994-12-22 1998-01-07 Astra Ab PHARMACEUTICAL COMPOSITION, PROCEDURE FOR THE MANUFACTURE OF A PROLIPOSOMA POWDER AS USED IN SUCH COMPOSITION, PROCEDURE FOR LAMANUFACTURE OF SUCH COMPOSITION, USE OF SUCH PHARMACEUTICAL COMPOSITION IN THE MANUFACTURE OF A DISPOSAL MEDICINAL PRODUCT.
US6515022B2 (en) * 1996-04-19 2003-02-04 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the treatment of lung diseases
IN187969B (en) * 1996-12-10 2002-08-03 Johnson & Johnson Consumer
DE19652790A1 (en) * 1996-12-18 1998-06-25 Hermes Fabrik Pharm Praeparate Pharmaceutical preparations
DE10012151A1 (en) 2000-03-13 2001-09-27 Gsf Forschungszentrum Umwelt Aerosol inhalant containing vitamin A compound in liposomes based on phosphatidylcholine, useful for treatment of tracheo-bronchial illnesses, especially chronic obstructive pulmonary disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US5556611A (en) * 1988-05-04 1996-09-17 Hermes Fabrik Pharmazeutischer Praparate Vitamin A aerosol-inhalant preparations and method
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5306483A (en) * 1989-07-27 1994-04-26 Scientific Development & Research, Inc. Phospholipid delivery system
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574623B2 (en) 2004-12-22 2013-11-05 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US8652526B2 (en) 2004-12-22 2014-02-18 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US20080107723A1 (en) * 2006-09-28 2008-05-08 Perkins Walter R Methods of Treating Pulmonary Distress
US8686052B2 (en) 2007-03-30 2014-04-01 Nitto Denko Corporation Targeting agent for cancer cell or cancer-associated fibroblast
US20090105179A1 (en) * 2007-09-14 2009-04-23 Nitto Denko Corporation Drug carriers
US8003621B2 (en) 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
US11154621B2 (en) * 2017-06-27 2021-10-26 Ohio State Innovation Foundation Liponucleotide-based therapy for COPD

Also Published As

Publication number Publication date
ATE319439T1 (en) 2006-03-15
US7074389B2 (en) 2006-07-11
EP1263422B1 (en) 2006-03-08
US20030064094A1 (en) 2003-04-03
WO2001068081A1 (en) 2001-09-20
JP2003528055A (en) 2003-09-24
US7476380B2 (en) 2009-01-13
AU2001252192A1 (en) 2001-09-24
ES2260213T3 (en) 2006-11-01
EP1263422A1 (en) 2002-12-11
DE10012151A1 (en) 2001-09-27
DE50109156D1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
US7476380B2 (en) Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD)
AU2013351934B2 (en) Prostacylin compositions and methods for using the same
JP2954343B2 (en) Pulmonary administration of pharmaceutically active substances
Haitsma et al. Exogenous surfactant as a drug delivery agent
Kellaway et al. Liposomes as drug delivery systems to the lung
WO2015138423A1 (en) Prostacylin compositions and methods for using the same
AU2007297691B2 (en) Pulmonary surfactant formulations and methods for promoting mucus clearance
US6770619B2 (en) Lung surfactant compositions with dynamic swelling behavior
AU2018307509A1 (en) Liposome compositions comprising weak acid drugs and uses thereof
CH684308A5 (en) Liposomes containing an allylamine.
US20140023696A1 (en) Treatment for idiopathic pulmonary fibrosis
EP1460967B1 (en) Composition and method for treatment of otitis externa
US6645467B2 (en) Composition and method for decreasing upper respiratory airway resistance
Taylor et al. Liposomes for pulmonary drug delivery
US20080107723A1 (en) Methods of Treating Pulmonary Distress
RU2538675C2 (en) Therapeutic combination containing lung surfactant and antioxidant enzymes
WO2003061668A1 (en) Use of pulmonary surfactant for the prevention of infectious diseases

Legal Events

Date Code Title Description
CC Certificate of correction
AS Assignment

Owner name: HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENT

Free format text: CHANGE OF NAME;ASSIGNOR:GSF-FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH;REEL/FRAME:023017/0537

Effective date: 20071219

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20130113